Robyn Hunter
Directeur/Membre du Conseil chez TENAX THERAPEUTICS, INC.
Fortune : - $ au 30/04/2024
Postes actifs de Robyn Hunter
Sociétés | Poste | Début | Fin |
---|---|---|---|
TENAX THERAPEUTICS, INC. | Directeur/Membre du Conseil | 28/01/2022 | - |
Independent Dir/Board Member | 28/01/2022 | - | |
Sotio Biotech AS
Sotio Biotech AS BiotechnologyHealth Technology Sotio Biotech AS is a member of the PPF Group and is based in Prague, Czechia. The Czech company is focused on developing cancer immunotherapies and has a robust clinical pipeline that includes a differentiated superagonist of the immuno-oncology target IL-15, currently being tested in phase II clinical trials. The pipeline also includes SOT102, a next-generation claudin-18.2-targeted antibody-drug conjugate, BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors, and other molecules approaching clinical stage such as SOT201, a next-generation PD-1-inhibiting cytokine. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, BOXR1030, and SOT102. | Directeur Financier/CFO | 01/08/2022 | - |
Historique de carrière de Robyn Hunter
Anciens postes connus de Robyn Hunter
Sociétés | Poste | Début | Fin |
---|---|---|---|
FORTRESS BIOTECH, INC. | Comptroller/Controller/Auditor | 01/08/2011 | 26/06/2017 |
Directeur Financier/CFO | 26/06/2017 | 16/08/2022 | |
Secrétaire Général | 01/06/2011 | 16/08/2022 | |
Treasurer | 01/06/2011 | 16/08/2022 | |
Schochet Associates, Inc. | Directeur Financier/CFO | 01/01/2006 | 01/05/2011 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Comptroller/Controller/Auditor | 01/08/2004 | 01/01/2006 |
Stackpole Corp. | Treasurer | 01/01/1990 | 01/01/2004 |
MUSTANG BIO, INC. | Secrétaire Général | - | - |
Treasurer | - | - | |
AVENUE THERAPEUTICS, INC. | Secrétaire Général | - | - |
CHECKPOINT THERAPEUTICS, INC. | Secrétaire Général | - | - |
Formation de Robyn Hunter
Union College (New York) | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 9 |
Canada | 2 |
République Tchèque | 2 |
Opérationnelle
Corporate Secretary | 4 |
Director of Finance/CFO | 3 |
Treasurer | 3 |
Sectorielle
Health Technology | 8 |
Producer Manufacturing | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 5 |
---|---|
TENAX THERAPEUTICS, INC. | Health Technology |
FORTRESS BIOTECH, INC. | Health Technology |
CHECKPOINT THERAPEUTICS, INC. | Health Technology |
AVENUE THERAPEUTICS, INC. | Health Technology |
MUSTANG BIO, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Health Technology |
Stackpole Corp. | Producer Manufacturing |
Schochet Associates, Inc. | |
Sotio Biotech AS
Sotio Biotech AS BiotechnologyHealth Technology Sotio Biotech AS is a member of the PPF Group and is based in Prague, Czechia. The Czech company is focused on developing cancer immunotherapies and has a robust clinical pipeline that includes a differentiated superagonist of the immuno-oncology target IL-15, currently being tested in phase II clinical trials. The pipeline also includes SOT102, a next-generation claudin-18.2-targeted antibody-drug conjugate, BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors, and other molecules approaching clinical stage such as SOT201, a next-generation PD-1-inhibiting cytokine. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, BOXR1030, and SOT102. | Health Technology |
- Bourse
- Insiders
- Robyn Hunter
- Expérience